Abstract: The present invention relates to a method for generating an antibody-payload conjugate by means of a microbial transglutaminase (MTG). The method comprises a step of conjugating a linker having a primary amine residue, said linker having the peptide structure (shown in N->C direction) (Aax)m-(Aax)(NH2)-(Aax)n-B-(Aax)o, or (Aax)m-B-(Aax)n-(Aax)(NH2)-(Aax)o, to a Gln residue comprised in the heavy or light chain of an antibody. Aax(NH2) is an amino acid, amino acid derivative or amino acid mimetic comprising a side chain having a primary amine group.

Abstract: Surface supported quantum wells with a confined surface state capture and stably confine neutral atoms and molecules in a nanometer precise environment. Depending on the physico-chemical conditions in the capturing process, the degree of occupancy, the temperature of the solid substrate, and/or the history of external stimuli like electromagnetic field pulses, these atoms, molecules or clusters assume unique configurations. The atoms or molecules are able to remain coupled to the quantum-well specific electronic state in the confinement and as such exhibit local and delocalized quantum entanglement. The capturing potential arises from the superposition of Pauli repulsion between the captured object and the quantum well-specific confined electronic state. This occurs within on-surface atomic or supramolecular assemblies or surface supported coordination or covalent networks.

Abstract: A device to host a crystallization medium, such as a solution, for crystal growth and a system for X-ray diffraction experiments to determine the atomic structure of crystals. A plurality of cells have a well, a sample holder placed in the well. The solution is hosted in the sample holder between thin-plates or one thin-plate. A cap seals an opening to the cell and each sample holder can be extracted independently from each well. A system for automated X-ray diffraction experiments for small crystals in the sample holder extracted from the wells utilizes an ultrasonic acoustic levitator to determine the crystal structure at atomic resolution. X-ray diffraction images are generated by scanning the X-ray beam over the levitated sample holder along a spiral trajectory by rotating the sample holder and moving in the direction perpendicular to the X-ray beam and the rotation axis at the same time.

Abstract: A detector system which can be switched between single photon counting and charge integrating mode depending on the application, the photon flux and energy. Although the space for electronics in a pixel or strip detector system is very limited (as each channel is limited by the pixel size), the reconfiguration of the analog chain and the logic/counter in this smart way yields to have a detector system allowing both modes of operation and, therefore, effectively combining the characteristics of an Eiger® single photon counting system and a Jungfrau® charge integrating pixel detector system into one single detector. Depending on the application, the flux and the photon energy, the operator is enabled to switch between single photon counting and charge integrating mode of operation.

Abstract: Elements of photonic devices with high aspect ratio patterns are fabricated. A stabilizing catalyst that forms a stable metal-semiconductor alloy allows to etch a substrate in vertical direction even at very low oxidant concentration without external bias or magnetic field. A metal layer on the substrate reacts with the oxidant contained in air and catalyzes the semiconductor etching by the etchant. Air in continuous flow at the metal layer allows to maintain constant the oxidant concentration in proximity of the metal layer. The process can continue for a long time in order to form very high aspect ratio structures in the order of 10,000:1. Once the etched semiconductor structure is formed, the continuous air flow supports the reactant species diffusing through the etched semiconductor structure to maintain a uniform etching rate. The continuous air flow supports the diffusion of reaction by-products to avoid poisoning of the etching reaction.

Abstract: A system counts photon interactions in an array of photosensitive diodes and addresses the issue of improving position resolution. Every photo-detector diode of the array is connected to a readout unit cell containing a high-gain charge-to-voltage amplifier, a shaper, at least two comparators with independent thresholds and at least one interpixel communication logic, receiving as input signals from comparator outputs of the same readout unit cell and of the neighboring readout unit cells. This logic is then connected to at least one counter, each counter followed by a counter readout. By means of the digital interpixel communication logic and the set of comparators with different thresholds in every readout unit cell, it is possible to determine the photon hit position in the detector with a higher position resolution than the physical photo-detector size including the removal of the corner effect in pixel detectors.

Abstract: Non-proton cationic impurities are removed from the ionomer in a proton exchange membrane of an electrochemical cell and from the anode side and cathode side catalyst layers. A supply path for an anode feed to the ionomer on the anode side of the proton exchange membrane and a supply path for a cathode feed to the ionomer on the cathode side of the proton exchange membrane are provided. A regenerating fluid with acidic pH is brought into contact with the ionomer on the cathode side of the proton exchange membrane to accomplish an ion exchange of the non-proton cationic impurities with protons and thus remove the non-proton cationic impurities from the ionomer into the regenerating fluid. This removes the non-proton cationic impurities from the ionomer of the electrochemical cell without increasing the risk of corrosion and without interrupting the process of the electrochemical cell.

Abstract: A green body for a 3D ceramic and/or metallic body is produced by providing a metal or a mixture of metals and/or a metalloid and/or a non-metal or mixtures thereof in form of at least one aqueous solutions, such as a metal nitrate solution; if more than one aqueous solutions are provided, they differ in composition and/or isotope concentration. One aqueous metal solution is mixed with a gelation fluid at a first temperature to suppress an internal gelation of the feed solution mixture prior to its ejection. The feed solution mixture is ejected by inkjet printing to the green body under construction. The ejected feed solution is heated mixture on the green body to a second temperature to fix it on the green body under construction. Several process steps are repeated according to a 3D production control model until a desired form of the green body is attained.

Abstract: The present invention is directed to a composition comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic agent, a nucleic acid encoding a fusion polypeptide comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic polypeptide agent as well as a corresponding recombinant vector and host cell comprising such a nucleic acid and preferably expressing said fusion polypeptide. The invention also relates to a kit of parts comprising at least one fibronectin binding polypeptide (FnBP), at least one diagnostic or therapeutic agent, and optionally one or more chemical agents for linking the fibronectin binding polypeptide (FnBP) to the diagnostic or therapeutic agent.

Abstract: The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.

Abstract: A gastrin analogue shows high uptake in CCK-2 receptor positive tumors and simultaneously a very low accumulation in the kidneys. This is achieved by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is an amino acid replacing methionine and X is a chemical group attached to the peptide for diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. Very suitable compounds with respect to a high tumor to kidney ratio are mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine which can be oxidized easily which is a disadvantage for clinical application under GMP due to the forms which may occur. The elimination of the methionine leads to a lower affinity to oxidation which in general favors the tumor-kidney-ratio. Ideally, the methionine is replaced by norleucine.

Abstract: An electrolyte membrane and method for generating the membrane provide a resistance as low as possible to minimize ohmic losses. The membrane has a low permeability for redox-active species. If redox-active species still cross the membrane, this transport is balanced during charge and discharge preventing a net vanadium flux and associated capacity fading. The membrane is mechanically robust, chemically stable in electrolyte solution, and low cost. A family of ion exchange membranes including a bilayer architecture achieves these requirements. The bilayer membrane includes two polymers, i) a polymer including N-heterocycles with electron lone pairs acting as proton acceptor sites and ii) a mechanically robust polymer acting as a support, which can be a dense cation exchange membrane or porous support layer. This bilayer architecture permits a very thin polymer film on a supporting polymer to minimize ohmic resistance and tune electrolyte transport properties of the membrane.

Abstract: A membrane with high ion selectivity, balancing influence on vanadium transport in all-vanadium redox-flow environment, high physicochemical stability and potentially low cost is an amphoteric ion exchange membrane with defined ratio of anion and cation exchange capacity, in particular for redox flow batteries. The membrane includes a mechanically robust and chemically resistant base polymer film (matrix), ion exchange groups covalently bound to the polymer matrix, being a mixture of anion and cation exchange groups, a comonomer including two anion exchange groups per molecule to yield a ratio of anion exchange groups to cation exchange groups of 1.5-4 (50-300% excess of anion exchange groups over cation exchange groups) to balance transport of positively charged redox-active ions, a quaternary bonded alpha-C atom in comonomers to protect the resulting polymer sterically against chemical degradation. Optionally, additional functional constituents, such as crosslinkers and/or antioxidants are provided.

Abstract: Method of determining GPCR and mutateable ligand binding ability, includes providing a well microtiter plate with well array having rows and columns, GPCR or rhodopsin in wells, and parent ligand mutant binding to GPCR when GPCR resides in conformation, contacting parent ligand mutants in wells with GPCR, coupling parent ligand to GPCR, and determining mutant ligand binding strength compared to standard parent ligand and GPCR by determining coupled mutant-GPCR complex in wells. Rhodopsin binding 403 mutants covering arrestin sequence provides functional 4th dimension arrestin crystal structures. Resulting single amino acid resolution functional maps reveal critical interactions in arrestin polar core and C-tail interrupted during activation. Amino acid patches reduce binding and act as direct binding rhodopsin interfaces. This and computational molecular docking active arrestin4 and light-activated rhodopsin develop arrestin-rhodopsin complex model.

Abstract: Site-specific modification of proteins with microbial transglutaminase (MTG) is a powerful and versatile strategy for a controlled modification of proteins under physiological conditions. Solid-phase microbead-immobilization is used to site-specifically and efficiently attach different functional molecules important for further downstream applications to proteins of therapeutic relevance including scFV, Fab-fragment and antibodies. MTG remained firmly immobilized with no detectable column bleeding and enzyme activity was sustained during continuous operation. Immobilized MTG shows enhanced selectivity towards a certain residue in the presence of several reactive residues which are all targeted when the conjugation was carried out in solution. The generation of dual site-specifically conjugated IgG1 with immobilized and MTG in solution is reported, i.e. site-specific conjugation to glutamine and lysine residues of IgG1 antibody.

Abstract: An exemplary mounting structure can be provided for interferometric imaging and an interferometric imaging apparatus comprising same. The mounting structure comprises at least one curved surface for receiving an interferometric grating to rest thereon. The surface can be provided having a plurality of apertures, whereas that the grating when so received, covers at least one of the apertures.

Abstract: A particle beam therapy system delivers a particle beam for particle radiation therapy to a target volume in a patient from different treatment angles. The particle beam enters an active static magnetic field region perpendicularly to a magnetic field. Magnets and/or coils generate a cylindrically shaped magnetic field system with magnetic fields oriented axially in the magnetic field system. The active magnetic field region has an outer radial guiding field region and an inner radial bending field region, with an arc scan magnet system at an outer edge, a first number of coils generating a static magnetic guiding field that is predominantly effective in the outer radial guiding field region, and a second number of coils predominantly effective in an inner radial bending field region. A treatment control system controls the magnets and/or coils to guide the particle beam according to a treatment plan for the target volume of the patient.

Abstract: A gastrin analogue shows high uptake in CCK-2 receptor positive tumors and simultaneously a very low accumulation in the kidneys. This is achieved by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is an amino acid replacing methionine and X is a chemical group attached to the peptide for diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. Very suitable compounds with respect to a high tumor to kidney ratio are mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine which can be oxidized easily which is a disadvantage for clinical application under GMP due to the forms which may occur. The elimination of the methionine leads to a lower affinity to oxidation which in general favors the tumor-kidney-ratio. Ideally, the methionine is replaced by norleucine.

Abstract: A gastrin analogue shows high uptake in CCK-2 receptor positive tumors and simultaneously a very low accumulation in the kidneys. This is achieved by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is an amino acid replacing methionine and X is a chemical group attached to the peptide for diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. Very suitable compounds with respect to a high tumor to kidney ratio are mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine which can be oxidized easily which is a disadvantage for clinical application under GMP due to the forms which may occur. The elimination of the methionine leads to a lower affinity to oxidation which in general favors the tumor-kidney-ratio. Ideally, the methionine is replaced by norleucine.

Abstract: The present application discloses in detail mutant ligands of the human G protein alpha-subunit -G?i1-, wherein at least one amino acid residue has been replaced with alanine if the at least one amino acid residue is a non-alanine residue, or at least one amino acid residue has been replace with glycine if the at least one amino acid residue is alanine and wherein the at least one amino acid residue is comprised in a first group containing of the amino acid residues with position R32A, K54A, I55A, I56A, H57A, R176A, E245A, Y296A, T327A, N331A, V332A and D350A or is comprised in a second group containing G42A, A59G, T177A, D200A, A226G, E297A, A300G and F334A or is comprised in a third group containing V50A, A59G, R178A 30 and K180A.